Drawing for BILTRUZO

USPTO serial 79230146

BILTRUZO

Reviewed by CopyMark Law Group

Reg. 5652089Status 709
Filing date
Status date
Registration date
Jan 15, 2019
Examiner
OSGOOD, KRYSTINA E
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BILTRUZO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kisuk Lee

Kisuk Lee Harness, Dickey & Pierce, PLC7700 Bonhomme Ave, Suite 400St. Louis, MO 63105UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of neurogenic detrusor overactivity; drugs being pharmaceutical preparations for the treatment of iron overload, migraine and diabetes; medicines for the treatment of cardiac, neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders; ethical medicinal preparations for prevention and treatment of low blood pressure; biological preparations for medical purposes for the treatment of infectious diseases, tumor-related diseases, auto-immune diseases, hormone-deficiency diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; vaccines; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune diseases; anti-infectives; antivirals; antibiotics; antiepileptic drugs, namely, anti-epileptic pharmaceutical preparations; dietary supplements; vitamin and mineral preparations for medical use; pharmaceuticals, namely, pharmaceutical preparations for the prevention of HIV/AIDS infection; pharmaceuticals, namely, pharmaceutical preparations for the treatment of HIV/AIDSSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 1, 2026INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 1, 2025C71TCANCELLED SECTION 71—
Jan 15, 2024REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Nov 5, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 12, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 25, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 7, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 6, 2019FIMPFINAL DISPOSITION PROCESSED—
Apr 15, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 15, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 30, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 30, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 26, 2018GPNXNOTIFICATION PROCESSED BY IB—
Oct 10, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Oct 10, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Oct 10, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 17, 2018ALIEASSIGNED TO LIE—
Sep 5, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 30, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Aug 30, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 30, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 30, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 22, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 22, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 22, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 22, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 22, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 22, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 8, 2018RFNTREFUSAL PROCESSED BY IB—
May 21, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 21, 2018RFRRREFUSAL PROCESSED BY MPU—
May 16, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 15, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 15, 2018DOCKASSIGNED TO EXAMINER—
Apr 17, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 13, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 12, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance